Redmond Asset Management LLC increased its position in shares of Inogen Inc (NASDAQ:INGN) by 4.3% in the second quarter, HoldingsChannel reports. The firm owned 23,227 shares of the medical technology company’s stock after purchasing an additional 954 shares during the period. Redmond Asset Management LLC’s holdings in Inogen were worth $1,551,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in INGN. Legal & General Group Plc lifted its holdings in shares of Inogen by 3.9% in the fourth quarter. Legal & General Group Plc now owns 17,963 shares of the medical technology company’s stock worth $2,230,000 after acquiring an additional 668 shares during the last quarter. Geode Capital Management LLC increased its position in Inogen by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 205,160 shares of the medical technology company’s stock valued at $25,474,000 after purchasing an additional 16,183 shares during the period. Retirement Systems of Alabama increased its position in Inogen by 1.8% during the 1st quarter. Retirement Systems of Alabama now owns 23,286 shares of the medical technology company’s stock valued at $2,221,000 after purchasing an additional 401 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Inogen during the 1st quarter valued at approximately $25,000. Finally, Chicago Capital LLC increased its position in Inogen by 66.1% during the 1st quarter. Chicago Capital LLC now owns 222,235 shares of the medical technology company’s stock valued at $21,195,000 after purchasing an additional 88,449 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.
INGN has been the subject of a number of recent analyst reports. Leerink Swann downgraded shares of Inogen from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 8th. BidaskClub downgraded shares of Inogen from a “sell” rating to a “strong sell” rating in a research report on Friday, August 9th. Needham & Company LLC downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Svb Leerink reissued a “market perform” rating and set a $47.00 target price (down previously from $78.00) on shares of Inogen in a research report on Thursday, August 8th. Finally, KeyCorp reissued a “hold” rating on shares of Inogen in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $82.17.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Wednesday, August 7th. The medical technology company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). The company had revenue of $101.10 million for the quarter, compared to analyst estimates of $106.88 million. Inogen had a return on equity of 13.34% and a net margin of 11.24%. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period last year, the business earned $0.65 EPS. On average, analysts anticipate that Inogen Inc will post 1.09 earnings per share for the current fiscal year.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Article: Buy Rating
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.